Literature DB >> 29523497

Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.

Peter Okokhere1, Andres Colubri2, Chukwuemeka Azubike3, Christopher Iruolagbe3, Omoregie Osazuwa3, Shervin Tabrizi4, Elizabeth Chin5, Sara Asad4, Ehi Ediale6, Mojeed Rafiu3, Donatus Adomeh7, Ikponmwosa Odia7, Rebecca Atafo8, Chris Aire7, Sylvanus Okogbenin9, Meike Pahlman10, Beate Becker-Ziaja10, Danny Asogun7, Terrence Fradet11, Ben Fry11, Stephen F Schaffner12, Christian Happi13, George Akpede14, Stephan Günther10, Pardis C Sabeti15.   

Abstract

BACKGROUND: Lassa fever is a viral haemorrhagic disease endemic to west Africa. No large-scale studies exist from Nigeria, where the Lassa virus (LASV) is most diverse. LASV diversity, coupled with host genetic and environmental factors, might cause differences in disease pathophysiology. Small-scale studies in Nigeria suggest that acute kidney injury is an important clinical feature and might be a determinant of survival. We aimed to establish the demographic, clinical, and laboratory factors associated with mortality in Nigerian patients with Lassa fever, and hypothesised that LASV was the direct cause of intrinsic renal damage for a subset of the patients with Lassa fever.
METHODS: We did a retrospective, observational cohort study of consecutive patients in Nigeria with Lassa fever, who tested positive for LASV with RT-PCR, and were treated in Irrua Specialist Teaching Hospital. We did univariate and multivariate statistical analyses, including logistic regression, of all demographic, clinical, and laboratory variables available at presentation to identify the factors associated with patient mortality.
FINDINGS: Of 291 patients treated in Irrua Specialist Teaching Hospital between Jan 3, 2011, and Dec 11, 2015, 284 (98%) had known outcomes (died or survived) and seven (2%) were discharged against medical advice. Overall case-fatality rate was 24% (68 of 284 patients), with a 1·4 times increase in mortality risk for each 10 years of age (p=0·00017), reaching 39% (22 of 57) for patients older than 50 years. Of 284 patients, 81 (28%) had acute kidney injury and 104 (37%) had CNS manifestations and thus both were considered important complications of acute Lassa fever in Nigeria. Acute kidney injury was strongly associated with poor outcome (case-fatality rate of 60% [49 of 81 patients]; odds ratio [OR] 15, p<0·00001). Compared with patients without acute kidney injury, those with acute kidney injury had higher incidence of proteinuria (32 [82%] of 39 patients) and haematuria (29 [76%] of 38) and higher mean serum potassium (4·63 [SD 1·04] mmol/L) and lower blood urea nitrogen to creatinine ratio (8·6 for patients without clinical history of fluid loss), suggesting intrinsic renal damage. Normalisation of creatinine concentration was associated with recovery. Elevated serum creatinine (OR 1·3; p=0·046), aspartate aminotransferase (OR 1·5; p=0·075), and potassium (OR 3·6; p=0·0024) were independent predictors of death.
INTERPRETATION: Our study presents detailed clinical and laboratory data for Nigerian patients with Lassa fever and provides strong evidence for intrinsic renal dysfunction in acute Lassa fever. Early recognition and treatment of acute kidney injury might significantly reduce mortality. FUNDING: German Research Foundation, German Center for Infection Research, Howard Hughes Medical Institute, US National Institutes of Health, and World Bank.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29523497      PMCID: PMC5984133          DOI: 10.1016/S1473-3099(18)30121-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  25 in total

1.  Infection disease surveillance update.

Authors:  Ruth Zwizwai
Journal:  Lancet Infect Dis       Date:  2016-01-26       Impact factor: 25.071

2.  Annual Incidence of Lassa Virus Infection in Southern Mali.

Authors:  David Safronetz; Nafomon Sogoba; Sory Ibrahim Diawara; Sidy Bane; Kyle Rosenke; Ousmane Maiga; Matt Boisen; Robert F Garry; Luis M Branco; L Robbin Lindsay; Sékou F Traoré; Heinz Feldmann; Seydou Doumbia
Journal:  Am J Trop Med Hyg       Date:  2017-01-16       Impact factor: 2.345

3.  Heparin-binding EGF-like growth factor contributes to reduced glomerular filtration rate during glomerulonephritis in rats.

Authors:  L Feng; G E Garcia; Y Yang; Y Xia; F B Gabbai; O W Peterson; J A Abraham; R C Blantz; C B Wilson
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

4.  Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury.

Authors:  Jay L Koyner; Vishal S Vaidya; Michael R Bennett; Qing Ma; Elaine Worcester; Shahab A Akhter; Jai Raman; Valluvan Jeevanandam; Micheal F O'Connor; Prasad Devarajan; Joseph V Bonventre; Patrick T Murray
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-26       Impact factor: 8.237

Review 5.  Empirical studies on usability of mHealth apps: a systematic literature review.

Authors:  Belén Cruz Zapata; José Luis Fernández-Alemán; Ali Idri; Ambrosio Toval
Journal:  J Med Syst       Date:  2015-01-20       Impact factor: 4.460

6.  Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012).

Authors:  Nnennaya A Ajayi; Chinedu G Nwigwe; Ben N Azuogu; Benson N Onyire; Elizabeth U Nwonwu; Lawrence U Ogbonnaya; Francis I Onwe; Tobin Ekaete; Stephan Günther; Kingsley N Ukwaja
Journal:  Int J Infect Dis       Date:  2013-07-17       Impact factor: 3.623

7.  Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever.

Authors:  Kristian G Andersen; Ilya Shylakhter; Shervin Tabrizi; Sharon R Grossman; Christian T Happi; Pardis C Sabeti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-03-19       Impact factor: 6.237

8.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Authors:  James E Robinson; Kathryn M Hastie; Robert W Cross; Rachael E Yenni; Deborah H Elliott; Julie A Rouelle; Chandrika B Kannadka; Ashley A Smira; Courtney E Garry; Benjamin T Bradley; Haini Yu; Jeffrey G Shaffer; Matt L Boisen; Jessica N Hartnett; Michelle A Zandonatti; Megan M Rowland; Megan L Heinrich; Luis Martínez-Sobrido; Benson Cheng; Juan C de la Torre; Kristian G Andersen; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Lansana Kanneh; Veronica J Koroma; Richard Fonnie; Simbirie C Jalloh; Brima Kargbo; Mohamed A Vandi; Momoh Gbetuwa; Odia Ikponmwosa; Danny A Asogun; Peter O Okokhere; Onikepe A Follarin; John S Schieffelin; Kelly R Pitts; Joan B Geisbert; Peter C Kulakoski; Russell B Wilson; Christian T Happi; Pardis C Sabeti; Sahr M Gevao; S Humarr Khan; Donald S Grant; Thomas W Geisbert; Erica Ollmann Saphire; Luis M Branco; Robert F Garry
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

Review 9.  Pathogenesis of Lassa fever.

Authors:  Nadezhda E Yun; David H Walker
Journal:  Viruses       Date:  2012-10-09       Impact factor: 5.048

10.  Aseptic Meningitis Caused by Lassa Virus: Case Series Report.

Authors:  Peter O Okokhere; Idowu A Bankole; Christopher O Iruolagbe; Benard E Muoebonam; Martha O Okonofua; Simeon O Dawodu; George O Akpede
Journal:  Case Rep Neurol Med       Date:  2016-11-13
View more
  34 in total

1.  Temporal analysis of Lassa virus infection and transmission in experimentally infected Mastomys natalensis.

Authors:  David Safronetz; Kyle Rosenke; Kimberley Meade-White; Angela Sloan; Ousmane Maiga; Sidy Bane; Cynthia Martellaro; Dana P Scott; Nafomon Sogoba; Heinz Feldmann
Journal:  PNAS Nexus       Date:  2022-07-13

2.  Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study.

Authors:  Jamie Strampe; Danny A Asogun; Emily Speranza; Meike Pahlmann; Ali Soucy; Sabrina Bockholt; Elisa Pallasch; Beate Becker-Ziaja; Sophie Duraffour; Nahid Bhadelia; Yemisi Ighodalo; Jennifer Oyakhilome; Emmanuel O Omomoh; Thomas Olokor; Donatus I Adomeh; Odia Ikponwonsa; Chris Aire; Ekaete Tobin; Nosa Akpede; Peter O Okokhere; Sylvanus A Okogbenin; George O Akpede; César Muñoz-Fontela; Ephraim Ogbaini-Emovon; Stephan Günther; John H Connor; Lisa Oestereich
Journal:  Lancet Infect Dis       Date:  2021-01-20       Impact factor: 71.421

3.  Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak.

Authors:  Matthew L Boisen; Eghosa Uyigue; John Aiyepada; Katherine J Siddle; Lisa Oestereich; Diana K S Nelson; Duane J Bush; Megan M Rowland; Megan L Heinrich; Philomena Eromon; Adeyemi T Kayode; Ikponmwosa Odia; Donatus I Adomeh; Ekene B Muoebonam; Patience Akhilomen; Grace Okonofua; Blessing Osiemi; Omigie Omoregie; Michael Airende; Jacqueline Agbukor; Solomon Ehikhametalor; Chris Okafi Aire; Sophie Duraffour; Meike Pahlmann; Wiebke Böhm; Kayla G Barnes; Samar Mehta; Mambu Momoh; John Demby Sandi; Augustine Goba; Onikepe A Folarin; Ephraim Ogbaini-Emovan; Danny A Asogun; Ekaete A Tobin; George O Akpede; Sylvanus A Okogbenin; Peter O Okokhere; Donald S Grant; John S Schieffelin; Pardis C Sabeti; Stephan Günther; Christian T Happi; Luis M Branco; Robert F Garry
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

4.  Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1-May 6, 2018.

Authors:  Elsie A Ilori; Yuki Furuse; Oladipupo B Ipadeola; Chioma C Dan-Nwafor; Anwar Abubakar; Oboma E Womi-Eteng; Ephraim Ogbaini-Emovon; Sylvanus Okogbenin; Uche Unigwe; Emeka Ogah; Olufemi Ayodeji; Chukwuyem Abejegah; Ahmed A Liasu; Emmanuel O Musa; Solomon F Woldetsadik; Clement L P Lasuba; Wondimagegnehu Alemu; Chikwe Ihekweazu
Journal:  Emerg Infect Dis       Date:  2019-06       Impact factor: 6.883

5.  Lassa hemorrhagic shock syndrome-on-a-chip.

Authors:  Huaqi Tang; Yasmine Abouleila; Alireza Mashaghi
Journal:  Biotechnol Bioeng       Date:  2020-12-04       Impact factor: 4.530

6.  Natural History of Aerosol Induced Lassa Fever in Non‑Human Primates.

Authors:  Isaac L Downs; Carl I Shaia; Xiankun Zeng; Joshua C Johnson; Lisa Hensley; David L Saunders; Franco Rossi; Kathleen A Cashman; Heather L Esham; Melissa K Gregory; William D Pratt; John C Trefry; Kyle A Everson; Charles B Larcom; Arthur C Okwesili; Anthony P Cardile; Anna Honko
Journal:  Viruses       Date:  2020-05-29       Impact factor: 5.048

7.  Population structure of Lassa Mammarenavirus in West Africa.

Authors:  Diego Forni; Manuela Sironi
Journal:  Viruses       Date:  2020-04-13       Impact factor: 5.048

Review 8.  Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.

Authors:  Francis Ifedayo Ibukun
Journal:  Viruses       Date:  2020-03-31       Impact factor: 5.048

9.  Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018.

Authors:  Katherine J Siddle; Philomena Eromon; Kayla G Barnes; Samar Mehta; Judith U Oguzie; Ikponmwosa Odia; Stephen F Schaffner; Sarah M Winnicki; Rickey R Shah; James Qu; Shirlee Wohl; Patrick Brehio; Christopher Iruolagbe; John Aiyepada; Eghosa Uyigue; Patience Akhilomen; Grace Okonofua; Simon Ye; Tolulope Kayode; Fehintola Ajogbasile; Jessica Uwanibe; Amy Gaye; Mambu Momoh; Bridget Chak; Dylan Kotliar; Amber Carter; Adrianne Gladden-Young; Catherine A Freije; Omigie Omoregie; Blessing Osiemi; Ekene B Muoebonam; Michael Airende; Rachael Enigbe; Benevolence Ebo; Iguosadolo Nosamiefan; Paul Oluniyi; Mahan Nekoui; Ephraim Ogbaini-Emovon; Robert F Garry; Kristian G Andersen; Daniel J Park; Nathan L Yozwiak; George Akpede; Chikwe Ihekweazu; Oyewale Tomori; Sylvanus Okogbenin; Onikepe A Folarin; Peter O Okokhere; Bronwyn L MacInnis; Pardis C Sabeti; Christian T Happi
Journal:  N Engl J Med       Date:  2018-10-17       Impact factor: 91.245

10.  Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria.

Authors:  Andrei R Akhmetzhanov; Yusuke Asai; Hiroshi Nishiura
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-06-24       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.